Search results for "Carbohydrate antigen 125"

showing 5 items of 5 documents

Long-term serial kinetics of N-terminal pro B-type natriuretic peptide and carbohydrate antigen 125 for mortality risk prediction following acute hea…

2017

Aim: Baseline values of N-terminal pro B-type natriuretic peptide (NT-proBNP) and carbohydrate antigen 125 (CA125) predict all-cause mortality in acute heart failure (AHF). However, there is limited information about the added prognostic benefit of using longitudinal values, and how this predictive ability is modified when modelling together. The aim of this study was to determine the mutually-adjusted association between the longitudinal trajectories of NT-proBNP and CA125 with all-cause mortality after an episode of AHF. Methods and results: We included 946 consecutive patients discharged for AHF. NT-proBNP and CA125 were measured at each physician-patient encounter (median (interquartile…

Malemedicine.medical_specialtyLongitudinal studyTime Factorsacute heart failuremedicine.drug_class030204 cardiovascular system & hematologyCritical Care and Intensive Care MedicineRisk Assessment03 medical and health sciences0302 clinical medicineInterquartile rangeRisk FactorsInternal medicineCause of DeathNatriuretic Peptide BrainmedicineNatriuretic peptideHumans030212 general & internal medicineMortalitycarbohydrate antigen 125Survival rateCause of deathAgedRetrospective StudiesHeart Failurebusiness.industrylongitudinal studyMembrane ProteinsRetrospective cohort studyGeneral MedicineBrain natriuretic peptidemedicine.diseasePrognosisPeptide FragmentsSurvival RateEndocrinologyB-type natriuretic peptideSpainHeart failureCA-125 AntigenAcute DiseaseCardiologyFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersFollow-Up StudiesEuropean heart journal. Acute cardiovascular care
researchProduct

Optimal carbohydrate antigen 125 cutpoint for identifying low-risk patients after admission for acute heart failure

2022

Introduction and objectives: Carbohydrate antigen 125 (CA125) has been shown to be useful for risk stratification in patients admitted with acute heart failure (AHF). We sought to determine a CA125 cutpoint for identifying patients at low risk of 1-month death or the composite of death/HF readmission following admission for AHF.Methods: The derivation cohort included 3231 consecutive patients with AHF. CA125 cutoff values with 90% negative predictive value (NPV) and sensitivity up to 85% were identified. The adequacy of these cutpoints and the risk of 1-month death/HF readmission was then tested using the Royston-Parmar method. The best cutpoint was selected and externally validated in a co…

medicine.medical_specialtyOptimal cutoffAntígeno carbohidrato 125MONOCLONAL-ANTIBODYendocrine system diseasesCarbohydratesAftercareInsuficiencia cardiaca aguda030204 cardiovascular system & hematologyWorsening Heart FailureCA12503 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansCutoffIn patientOutcomeHeart FailureNATRIURETIC PEPTIDEbusiness.industryMORTALITYPronósticoGeneral MedicineCongestiónPrognosismedicine.diseasePredictive valuePatient Dischargefemale genital diseases and pregnancy complicationsAntígeno carbohidrato 125; CA125; Carbohydrate antigen 125; Congestion; Congestión; Insuficiencia cardiaca aguda; Outcome; Pronóstico; Worsening Heart Failure; Acute Disease; CA-125 Antigen; Carbohydrates; Humans; Patient Discharge; Prognosis; Aftercare; Heart FailureCarbohydrate antigen 125CA-125 AntigenHeart failureAcute DiseaseCohortRisk stratificationCongestionbusinessCarbohydrate antigenRevista Española de Cardiología (English Edition)
researchProduct

Differential mortality association of loop diuretic dosage according to blood urea nitrogen and carbohydrate antigen 125 following a hospitalization …

2012

Recent observations in chronic stable heart failure suggest that high-dose loop diuretics (HDLDs) have detrimental prognostic effects in patients with high blood urea nitrogen (BUN), but recent findings have also indicated that diure- tics may improve renal function. Carbohydrate antigen 125 (CA125) has been shown to be a surrogate of systemic congestion. We sought to explore whether BUN and CA125 modulate the mortality risk associated with HDLDs following a hospitalization for acute heart failure (AHF). Methods and results We analysed 1389 consecutive patients discharged for AHF. CA125 and BUN were measured at a mean of 72+12 h after admission. HDLDs (≥120 mg/day in furosemide equivalent d…

Malemedicine.medical_specialtymedicine.drug_classRenal functionGastroenterologyRisk AssessmentLoop diureticsBlood Urea NitrogenCohort StudiesSodium Potassium Chloride Symporter InhibitorsFurosemideInternal medicinemedicineHumansProspective StudiesMortalityProspective cohort studyBlood urea nitrogenAgedAged 80 and overHeart Failurebusiness.industryHazard ratioFurosemideAcute heart failureLoop diureticMiddle Agedmedicine.diseaseConfidence intervalfemale genital diseases and pregnancy complicationsHospitalizationBlood urea nitrogenEndocrinologyCarbohydrate antigen 125Heart failureCA-125 AntigenAcute DiseaseFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersmedicine.drugFollow-Up StudiesEuropean journal of heart failure
researchProduct

Early urinary sodium trajectory and risk of adverse outcomes in acute heart failure and renal dysfunction.

2021

Introduction and objectives: Urinary sodium (UNa+) has emerged as a useful biomarker of poor clinical outcomes in acute heart failure (AHF). Here, we sought to evaluate: a) the usefulness of a single early determination of UNa+ for predicting adverse outcomes in patients with AHF and renal dysfunction, and b) whether the change in UNa+ at 24 hours (Delta UNa24 h) adds any additional prognostic information over baseline values. Methods: This is a post-hoc analysis of a multicenter, open-label, randomized clinical trial (IMPROVE-HF) (ClinicalTrials.gov NCT02643147) that randomized 160 patients with AHF and renal dysfunction on admission to a) the standard diuretic strategy, or b) a carbohydra…

medicine.medical_specialtyRenal failureTratamiento diuréticoAntígeno carbohidrato 125medicine.medical_treatmentRenal function030204 cardiovascular system & hematologyInsuficiencia cardiaca agudaGastroenterologylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInterquartile rangeInternal medicineBiomarker-guided therapyEnsayo clínicoTerapia guiada por biomarcadoresClinical endpointHumansMedicineDiureticsAgedAged 80 and overHeart Failurebusiness.industryFallo renalSodiumAcute heart failureGeneral Medicinemedicine.diseaseClinical trialClinical trialAcute heart failure Antígeno carbohidrato 125 Biomarker-guided therapy Carbohydrate antigen 125 Clinical trial Diuretic treatment Ensayo clínico Fallo renal Insuficiencia cardiaca aguda Renal failure Terapia guiada por biomarcadores Tratamiento diuréticoCarbohydrate antigen 125Heart failureAcute DiseaseDiuretic treatmentBiomarker (medicine)Kidney DiseasesDiureticbusiness
researchProduct

CA125-Guided Diuretic Treatment Versus Usual Care in Patients With Acute Heart Failure and Renal Dysfunction

2020

BACKGROUND: The optimal diuretic treatment strategy for patients with acute heart failure and renal dysfunction remains unclear. Plasma carbohydrate antigen 125 (CA125) is a surrogate of fluid overload and a potentially valuable tool for guiding decongestion therapy. The aim of this study was to determine if a CA125-guided diuretic strategy is superior to usual care in terms of short-term renal function in patients with acute heart failure and renal dysfunction at presentation. METHODS: This multicenter, open-label study randomized 160 patients with acute heart failure and renal dysfunction into 2 groups (1:1). Loop diuretics doses were established according to CA125 levels in the CA125-gui…

Maleendocrine system diseasesPREDICTIONmedicine.medical_treatmentUrine030204 cardiovascular system & hematologyKidney Function TestsCONGESTIONBiomarker guided-therapy0302 clinical medicineSodium Potassium Chloride Symporter InhibitorsFurosemideNatriuretic peptideMedicineRenal Insufficiency030212 general & internal medicinePrecision MedicineANTIGEN CARBOHYDRATE 125Aged 80 and overFurosemideGeneral MedicineDiuretic treatmentEUROPEAN-SOCIETYClinical trialFemaleTRIALmedicine.drugmedicine.medical_specialtyRenal failureSTRATEGIESmedicine.drug_classUrologyRenal function03 medical and health sciencesHumansIn patientAgedHeart FailureSERUM CREATININENATRIURETIC PEPTIDEbusiness.industryMORTALITYMembrane ProteinsAcute heart failuremedicine.diseaseClinical trialCarbohydrate antigen 125CA-125 AntigenHeart failureDiuretic treatmentDiureticbusinessCARDIORENAL SYNDROME
researchProduct